Attached files
| file | filename |
|---|---|
| S-1MEF - S-1MEF - PRECIGEN, INC. | d580459ds1mef.htm |
| EX-5.1 - EX-5.1 - PRECIGEN, INC. | d580459dex51.htm |
| EX-23.1 - EX-23.1 - PRECIGEN, INC. | d580459dex231.htm |
| EX-23.2 - EX-23.2 - PRECIGEN, INC. | d580459dex232.htm |
| EX-23.3 - EX-23.3 - PRECIGEN, INC. | d580459dex233.htm |
| EX-23.5 - EX-23.5 - PRECIGEN, INC. | d580459dex235.htm |
EXHIBIT 23.4
Consent of Independent Registered Public Accounting Firm
We consent to the use in this Registration Statement on Form S-1MEF of Intrexon Corporation of our report dated March 18, 2013, relating to our audit of the financial statements of ZIOPHARM Oncology, Inc., appearing in the Prospectus, which is part of this Registration Statement. Our report dated March 18, 2013 relating to the financial statements includes an emphasis paragraph relating to an uncertainty as to the Company’s ability to continue as a going concern.
We also consent to the reference to our firm under the captions “Experts” in such Prospectus.
/s/ McGladrey LLP
Boston, Massachusetts
August 6, 2013